Skip to main content
iwCLL 2023 Main banner
Final Program


iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Live Stream

(1549277) Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

Friday, October 6, 2023
9:05 AM – 9:10 AM EDT
Location: HCC, MR 302/304, Level 3

    Primary Author; Presenting Author(s)

  • Marek Mraz, MD, PhD

    PI
    CEITEC MU, Brno, Czech Rep.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

    • Co-Author(s)

  • LO

    Laura Ondrisova, MSc

    PhD Student
    CEITEC MU, Brno, Czech Rep.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • Vaclav Seda, PhD

    Student
    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • EH

    Eva Hoferkova, MSc

    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • GC

    Giorgia Chiodin, PhD

    Cancer Sciences, Faculty of Medicine, University of Southampton
    Southampton, United Kingdom

  • KH

    Krystof Hlavac, MSc

    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • LK

    Lenka Kostalova, MSc

    researcher
    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • GM

    Gabriela Mladonicka Pavlasova, PhD

    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • DF

    Daniel Filip, MSc

    PhD student
    CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • Pedro F. Faria Zeni, PhD

    PhD Student
    CEITEC MU
    Brno, Jihomoravsky kraj, Czech Republic

  • JO

    Jan Oppelt, PhD

    Postdoc
    CEITEC MU, Czech Republic

  • AP

    Anna Panovska, MD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • KP

    Karla Plevova, PhD

    junior researcher
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • SP

    Sarka Pospisilova, Professor

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • MĹ

    Martin Ĺ imkoviÄŤ, MD, PhD

    Consultant
    4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové
    Hradec Králové, Kralovehradecky kraj, Czech Republic

  • FV

    Filip VrbackĂ˝, RNDr., PhD.

    Consultant
    4th Department of Internal Medicine – Hematology, University Hospital and Charles University Faculty of Medicine in Hradec Králové, Pardubicky kraj, Czech Republic

  • DL

    Daniel Lysak, MD

    Department of Haematology and Oncology, University Hospital Pilsen
    Pilsen, Czech Republic

  • SF

    Stacey M. Fernandes, BS

    Dana-Farber Cancer Institute
    Boston, MA, United States

  • Matthew S. Davids, MD, MMSc

    Director, Clinical Research, Division of Lymphoma
    Dana-Farber Cancer Institute (DFCI)
    Boston, MA, United States

  • AM

    Alba Maiques-Diaz, PhD

    Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
    Barcelona, Spain

  • SC

    Stella Charalampopoulou, MSc

    Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
    Barcelona, Spain

  • JM

    Jose I. Martin-Subero, PhD

    Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
    Barcelona, Spain

  • Jennifer R. Brown, MD, PhD

    Director, CLL Center & Institute Physician, DFCI; Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, HMS
    Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI); Department of Medicine, Harvard Medical School (HMS)
    Boston, MA, United States

  • Michael Doubek, Professor

    Vice-head of the Department of Internal Medicine - Hematology and Oncology and Department of Medical Genetics and Genomics.
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • FF

    Francesco Forconi, MD, DM, PhD, FRCPath

    Cancer Sciences, Faculty of Medicine, University of Southampton
    Southampton, England, United Kingdom

  • JM

    Jiri Mayer, Professor

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

Disclosure(s):
Marek Mraz, MD, PhD: No financial relationships to disclose
Jennifer R. Brown, MD, PhD: No relevant disclosure to display